Ocugen to Present at April 2026 Investor and Industry Conferences
Rhea-AI Summary
Ocugen (NASDAQ: OCGN) will present at two industry investor conferences the week of April 27–29, 2026. Dr. Shankar Musunuri will present at Oppenheimer’s Innovation on the Island in Puerto Rico on April 28 at 8:20 a.m. AST; Abhi Gupta will present at Meeting on the Med in Rome on April 28 at 4:30 p.m. CEST. Executive leadership will discuss the company’s modifier gene therapy platform and remarks note a planned BLA submission for OCU400 later this year.
Positive
- None.
Negative
- None.
News Market Reaction – OCGN
In the Apr 23 session, OCGN declined 0.60%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 01 | Clinical trial update | Positive | -1.1% | Early completion of dosing in Phase 2/3 GARDian3 trial for OCU410ST. |
| Mar 24 | Clinical data readout | Positive | -8.6% | Positive 12-month Phase 2 ArMaDa data for OCU410 in geographic atrophy. |
| Mar 23 | Event/webcast notice | Neutral | +2.9% | Announcement of webcast to discuss Phase 2 OCU410 clinical trial data. |
| Mar 04 | Earnings and update | Positive | +5.4% | Q4 and full-year 2025 results with pipeline and financing progress details. |
| Mar 02 | Clinical trial milestone | Positive | +6.6% | Completion of Phase 3 liMeliGhT enrollment for OCU400 in retinitis pigmentosa. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and business updates often led to mixed reactions, with some key clinical wins followed by negative or muted price moves, while certain milestones and financial updates saw stronger positive alignment.
Over the past few months, Ocugen has advanced multiple late-stage ophthalmology programs. In March–April 2026, it reported positive Phase 2 ArMaDa data for OCU410, completed dosing in the GARDian3 Phase 2/3 trial for OCU410ST, and finished enrollment in the Phase 3 liMeliGhT trial for OCU400. A Q4 and full‑year 2025 update highlighted financing that extended runway into Q4 2026. Against this backdrop, the current conference-presentations announcement fits a pattern of ongoing investor outreach around an advancing gene-therapy pipeline.
Key Terms
atmp medical
modifier gene therapy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at Oppenheimer’s 3rd Annual Innovation on the Island Biotech Summit from April 27-29, 2026 in Rio Grande, Puerto Rico; and Abhi Gupta, MBA, Executive Vice President, Commercial and Business Development at Ocugen will present at the 2026 Cell & Gene Meeting on the Mediterranean being held April 28-30, 2026 in Rome, Italy.
“I look forward to sharing our story with new audiences and building enthusiasm for why now is the time to get to know Ocugen,” said Dr. Musunuri. “Our gene-agnostic approach to addressing all mutations related to major blindness diseases has the potential to be first-in-class—disrupting existing treatment paradigms and bringing gene therapy to the masses. With our planned BLA submission for OCU400 beginning later this year, commercialization is within reach.”
Innovation on the Island will include panels, company presentations, and networking opportunities. Biotech investors based in Puerto Rico as well as the continental United States will be in attendance.
The Cell & Gene Meeting on the Med brings together the ATMP community from Europe and beyond and covers a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing. Ocugen is a proud member and collaborator with the meeting’s organizer, the Alliance for Regenerative Medicine.
Details on the Company presentations are as follows:
Innovation on the Island
Date: Tuesday, April 28, 2026
Time: 8:20 a.m. AST
Location: Four Seasons Bahia Beach Resort
Meeting on the Med
Date: Tuesday, April 28, 2026
Time: 4:30 p.m. CEST
Location: Rome Cavalieri, Salone dei Cavalieri, Section 1
Executive Leadership looks forward to providing updates on Ocugen’s novel modifier gene therapy platform, including near-term key catalysts, during one-on-one opportunities at these important conferences.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late-stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com
